New research published in JAMA finds a deep concentration of PBM services are evident across all three payer markets, especially Medicare Part D.

CMS has issued a final rule that put an end to PBM’s retroactive application of direct and indirect remuneration (DIR) fees, requiring that they be reflected in the negotiated price the patient pays at the pharmacy counter. The rule included all price concessions beginning on January 1, 2024.